Article

Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al.. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369: 2097-2105

Department of Neurological Surgery, Weill Medical College of Cornell University, New York, NY, USA.
The Lancet (Impact Factor: 45.22). 07/2007; 369(9579):2097-105. DOI: 10.1016/S0140-6736(07)60982-9
Source: PubMed

ABSTRACT Dopaminergic neuronal loss in Parkinson's disease leads to changes in the circuitry of the basal ganglia, such as decreased inhibitory GABAergic input to the subthalamic nucleus. We aimed to measure the safety, tolerability, and potential efficacy of transfer of glutamic acid decarboxylase (GAD) gene with adeno-associated virus (AAV) into the subthalamic nucleus of patients with Parkinson's disease.
We did an open label, safety and tolerability trial of unilateral subthalamic viral vector (AAV-GAD) injection in 11 men and 1 woman with Parkinson's disease (mean age 58.2, SD=5.7 years). Four patients received low-dose, four medium-dose, and four high-dose AAV-GAD at New York Presbyterian Hospital. Inclusion criteria consisted of Hoehn and Yahr stage 3 or greater, motor fluctuations with substantial off time, and age 70 years or less. Patients were assessed clinically both off and on medication at baseline and after 1, 3, 6, and 12 months at North Shore Hospital. Efficacy measures included the Unified Parkinson's Disease Rating Scale (UPDRS), scales of activities of daily living (ADL), neuropsychological testing, and PET imaging with 18F-fluorodeoxyglucose. The trial is registered with the ClinicalTrials.gov registry, number NCT00195143.
All patients who enrolled had surgery, and there were no dropouts or patients lost to follow-up. There were no adverse events related to gene therapy. Significant improvements in motor UPDRS scores (p=0.0015), predominantly on the side of the body that was contralateral to surgery, were seen 3 months after gene therapy and persisted up to 12 months. PET scans revealed a substantial reduction in thalamic metabolism that was restricted to the treated hemisphere, and a correlation between clinical motor scores and brain metabolism in the supplementary motor area.
AAV-GAD gene therapy of the subthalamic nucleus is safe and well tolerated by patients with advanced Parkinson's disease, suggesting that in-vivo gene therapy in the adult brain might be safe for various neurodegenerative diseases.

Download full-text

Full-text

Available from: Helen L Fitzsimons, Aug 29, 2015
0 Followers
 · 
220 Views
  • Source
    • "Rigorous toxicity , and serological and cellular immune assessments have been performed for AAV1 , AAV2 , AAV5 AAV8 and AAVrh10 . These serotypes have been used in clinical trials for lipoprotein lipase deficiency ( LPLD ; AAV - 1 ; Scott , 2015 ) , Canavan disease , PD and AD ( AAV - 2 ; Leone et al . , 2000 , 2012 ; Kaplitt et al . , 2007 ; Richardson et al . , 2011 ; Bartus et al . , 2013 ; Rafii et al . , 2014 ) , liver mediated diseases ( AAV5 ; Grosios and Pañeda , 2013 ) , San Fillipo B ( AAV5 , AAVrh10 ; Tardieu et al . , 2014 ) 1 and Hemeophilia B ( AAV - 5 , AAV - 8 ; Nathwani et al . , 2014 ) . Although most humans have natural occurring neutralizing antibodies "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical phase I/II studies have demonstrated the safety of gene therapy for a variety of central nervous system disorders, including Canavan's, Parkinson's (PD) and Alzheimer's disease (AD), retinal diseases and pain. The majority of gene therapy studies in the CNS have used adeno-associated viral vectors (AAV) and the first AAV-based therapeutic, a vector encoding lipoprotein lipase, is now marketed in Europe under the name Glybera. These remarkable advances may become relevant to translational research on gene therapy to promote peripheral nervous system (PNS) repair. This short review first summarizes the results of gene therapy in animal models for peripheral nerve repair. Secondly, we identify key areas of future research in the domain of PNS-gene therapy. Finally, a perspective is provided on the path to clinical translation of PNS-gene therapy for traumatic nerve injuries. In the latter section we discuss the route and mode of delivery of the vector to human patients, the efficacy and safety of the vector, and the choice of the patient population for a first possible proof-of-concept clinical study.
    Frontiers in Molecular Neuroscience 07/2015; 8:32. DOI:10.3389/fnmol.2015.00032 · 4.08 Impact Factor
    • "An open label trial evaluated the safety and tolerability of unilateral subthalamic viral vector (AAV-GAD) in 12 patients with advanced PD, and reported significant improvements in motor symptoms 3 months after gene therapy that persisted for up to 12 months. No adverse events related to gene therapy were observed (Kaplitt et al., 2007). These findings suggested that AAV-GAD gene therapy of the subthalamic nucleus was safe and well tolerated by patients with advanced PD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of Parkinson’s disease (PD) increases with age and is projected to increase in parallel to the rising average age of the population. The disease can have significant health-related, social, and financial implications not only for the patient and the caregiver, but for the health care system as well. While the neuropathology of this neurodegenerative disorder is fairly well understood, its etiology remains a mystery, making it difficult to target therapy. The currently available drugs for treatment provide only symptomatic relief and do not control or prevent disease progression, and as a result patient compliance and satisfaction are low. Several emerging pharmacotherapies for PD are in different stages of clinical development. These therapies include adenosine A2A receptor antagonists, glutamate receptor antagonists, monoamine oxidase inhibitors, anti-apoptotic agents, and antioxidants such as coenzyme Q10, N-acetyl cysteine, and edaravone. Other emerging non-pharmacotherapies include viral vector gene therapy, microRNAs, transglutaminases, RTP801, stem cells and glial derived neurotrophic factor (GDNF). In addition, surgical procedures including deep brain stimulation, pallidotomy, thalamotomy and gamma knife surgery have emerged as alternative interventions for advanced PD patients who have completely utilized standard treatments and still suffer from persistent motor fluctuations. While several of these therapies hold much promise in delaying the onset of the disease and slowing its progression, more pharmacotherapies and surgical interventions need to be investigated in different stages of PD. It is hoped that these emerging therapies and surgical procedures will strengthen our clinical aramamentum for improved treatment of PD.
    Pharmacology [?] Therapeutics 11/2014; 144(2). DOI:10.1016/j.pharmthera.2014.05.010 · 7.75 Impact Factor
  • Source
    • "Moreover, Y4 receptor knockout mice have also revealed a potential role for Y4 receptors in both anxiety-and depression-like behaviours (Painsipp et al., 2008). Gene therapy with viral vectors is under investigation as a future treatment option for brain disorders, particularly of neurological origin (Alexander et al., 2010; Hudry et al., 2010; Kaplitt et al., 2007; Manfredsson and Mandel, 2010; Mitra and Sapolsky, 2010; Woldbye Funding: This work was supported by The "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuropeptide Y (NPY) causes anxiolytic- and antidepressant-like effects after central administration in rodents. These effects could theoretically be utilized in future gene therapy for anxiety and depression using viral vectors for induction of overexpression of NPY in specific brain regions. Using a recombinant adeno-associated viral (rAAV) vector, we addressed this idea by testing effects on anxiolytic- and depression-like behaviours in adult mice after overexpression of NPY transgene in the amygdala and/or hippocampus, two brain regions implicated in emotional behaviours. In the amygdala, injections of rAAV-NPY caused significant anxiolytic-like effect in the open field, elevated plus maze, and light-dark transition tests. In the hippocampus, rAAV-NPY treatment was associated with anxiolytic-like effect only in the elevated plus maze. No additive effect was observed after combined rAAV-NPY injection into both the amygdala and hippocampus where anxiolytic-like effect was found in the elevated plus maze and light-dark transition tests. Antidepressant-like effects were not detected in any of the rAAV-NPY injected groups. Immobility was even increased in the tail suspension and forced swim tests after intra-amygdaloid rAAV-NPY. Taken together, the present data show that rAAV-NPY treatment may confer non-additive anxiolytic-like effect after injection into the amygdala or hippocampus, being most pronounced in the amygdala.
    Neuropeptides 09/2014; 48(6). DOI:10.1016/j.npep.2014.09.004 · 2.55 Impact Factor
Show more